GlassScriptPhysician profile
Jyes A Querubin
NPI 1154688604
$8,384.23
in general payments reported to CMS, 2019-2025
56 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 77% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $532 · 2021: $445 · 2022: $999 · 2023: $3,402 · 2024: $940 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206 · Consulting Fee: $1,800 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.23 |
| Consulting Fee | $1,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,995.89 | 2023-2025 | Daybue, Nuplazid |
| Ucb, INC. | $922.73 | 2022-2025 | Fintepla, Zilbrysq, Nayzilam |
| Biogen, INC. | $489.64 | 2022-2025 | Vumerity, Tysabri, Avonex |
| Jazz Pharmaceuticals INC. | $442.07 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $407.94 | 2019-2025 | Qelbree, Trokendi Xr, Oxtellar Xr |
| Livanova USA, INC. | $388.35 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $302.29 | 2020-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $241.66 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $190.63 | 2022-2025 | |
| Greenwich Biosciences, INC. | $175.01 | 2020-2021 | |
| Neurelis, INC. | $170.81 | 2021-2025 | Valtoco |
| Neuropace, INC. | $148.25 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $142.70 | 2023-2025 | Dysport |
| Grifols USA, LLC | $138.32 | 2023-2025 | Gamunex-C |
| Sk Life Science, INC. | $136.83 | 2023-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyes Querubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.